Loader

Pathways

PathWhiz ID Pathway Meta Data

PW128350

Pw128350 View Pathway
drug action

Phenelzine Amine Oxidase Serotonin Antidepressant Action Pathway

Homo sapiens
Phenelzine, also known as Nardil, is a monoamine oxidase inhibitor (MAOIs). This drug is used as an antidepressant and it is also effective in the treatment of panic disorder and social anxiety disorder. The monoamine oxidase is an enzyme that catalyzes the oxidative deamination of many amines like serotonin, norepinephrine, epinephrine, and dopamine. There are 2 isoforms of this protein: A and B. The first one is found in cells located in the periphery and breakdown serotonin, norepinephrine, epinephrine, dopamine, and tyramine. The second one, the B isoform, breakdowns phenylethylamine, norepinephrine, epinephrine, dopamine, and tyramine. This isoform is found in the extracellular tissues and mostly in the brain. The mechanism of action of the MAOIs is still not determined, it is thought that they act by increasing free serotonin and norepinephrine (shown in this pathway) concentrations and/or by altering the concentrations of other amines in the CNS. MAO A inhibition is thought to be more relevant to antidepressant activity than the inhibition caused by MAO B. Selective MAO B inhibitors have no antidepressant effects. Phenelzine inhibits both isoforms causing an elevation in brain levels of catecholamines (like norepinephrine) and serotonin. This drug is administered as an oral tablet.

PW144889

Pw144889 View Pathway
drug action

Phenelzine Drug Metabolism Action Pathway

Homo sapiens

PW146647

Pw146647 View Pathway
drug action

Pheneticillin Drug Metabolism Action Pathway

Homo sapiens

PW132353

Pw132353 View Pathway
metabolic

Phenformin Drug Metabolism

Homo sapiens
Phenformin is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Phenformin passes through the liver and is then excreted from the body mainly through the kidney.

PW145015

Pw145015 View Pathway
drug action

Phenformin Drug Metabolism Action Pathway

Homo sapiens

PW132577

Pw132577 View Pathway
metabolic

Phenindamine Drug Metabolism

Homo sapiens
Phenindamine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Phenindamine passes through the liver and is then excreted from the body mainly through the kidney.

PW145483

Pw145483 View Pathway
drug action

Phenindamine Drug Metabolism Action Pathway

Homo sapiens

PW176592

Pw176592 View Pathway
drug action

Phenindamine H1 Antihistamine Smooth Muscle Relaxation Action Pathway

Homo sapiens
Phenindamine is an H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage. Phenindamine also inhibits the H1 histamine receptor on bronchiole smooth muscle myocytes. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin.Calcium bound calmodulin is required for the activation of myosin light chain kinase. This prevents the phosphorylation of myosin light chain 3, causing an accumulation of myosin light chain 3. This causes muscle relaxation, opening up the bronchioles in the lungs, making breathing easier.

PW062141

Pw062141 View Pathway
drug action

Phenindamine H1-Antihistamine Action

Homo sapiens
Phenindamine is a first-generation tricyclic H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW176685

Pw176685 View Pathway
drug action

Phenindamine H1-Antihistamine Blood Vessel Constriction Action Pathway

Homo sapiens
Phenindamine is an H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage. Phenindamine inhibits the H1 histamine receptor on blood vessel endothelial cells. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin. Calcium bound calmodulin is required for the activation of the calmodulin-binding domain of nitric oxide synthase. The inhibition of nitric oxide synthesis prevents the activation of myosin light chain phosphatase. This causes an accumulation of myosin light chain-phosphate which causes the muscle to contract and the blood vessel to constrict, decreasing the swelling and fluid leakage from the blood vessels caused by allergens.